Verified Nov 2026
Other
·

San Diego, California
·
Since 1992
Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and headquartered in San Diego, California, with 1,000–5,000 employees and estimated revenue of $1–5 billion. It develops FDA-approved treatments and investigational therapies for neurological, neuroendocrine, and neuropsychiatric disorders, serving patients with movement disorders and rare pediatric epilepsies. The company acquired Soleno Therapeutics in 2026 to expand into metabolic and endocrine rare diseases.
Neurocrine Biosciences at a glance
Revenue
$1-5B
Est. band
Employees
1,000-5,000
Founded
1992
Headquarters
San Diego, California
Import activity
3
Industries
Automotive
Electric Vehicles
Medical
Sourcing and import activity
From US customs bill-of-lading records
US sea imports
3
Named foreign suppliers
3
Top origins
Italy · Germany · Netherlands

Shared foreign counterparties do not establish that these companies buy from Neurocrine Biosciences.
What this tells a buyer
Neurocrine received exclusive worldwide rights to SCO-483, a selective melanocortin 2 receptor antagonist, in April 2026, and completed a $2.9 billion acquisition of Soleno Therapeutics in the same month to broaden its rare disease portfolio.
The company markets four FDA-approved treatments in the United States, including INGREZZA for tardive dyskinesia and dyskinetic cerebral palsy, with an active pipeline of investigational therapies.
Neurocrine maintains a supply chain spanning Europe, with documented shipments from suppliers in Italy, Germany, Switzerland, and the Netherlands.
Source: US customs bill-of-lading records and public filings · Last verified Nov 16, 2026
STABILITY SIGNALS
Established & active
34 years in operation (founded 1992).
3 US import shipments on record.
Overview
Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and headquartered in San Diego, California, with 1,000–5,000 employees and estimated revenue of $1–5 billion. It develops FDA-approved treatments and investigational therapies for neurological, neuroendocrine, and neuropsychiatric disorders, serving patients with movement disorders and rare pediatric epilepsies. The company acquired Soleno Therapeutics in 2026 to expand into metabolic and endocrine rare diseases.
At a glance
Attribute | Detail |
|---|---|
Founded | 1992 |
Headquarters | San Diego, California |
Employees | 1,000-5,000 |
Revenue | $1-5B (estimated) |
What Neurocrine Biosciences makes
The company markets four FDA-approved treatments in the United States, including INGREZZA for tardive dyskinesia and dyskinetic cerebral palsy, with an active pipeline of investigational therapies.
Trade and customs footprint
Neurocrine received exclusive worldwide rights to SCO-483, a selective melanocortin 2 receptor antagonist, in April 2026, and completed a $2.9 billion acquisition of Soleno Therapeutics in the same month to broaden its rare disease portfolio. US customs bill-of-lading records list 3 inbound shipments across 3 foreign suppliers, with top origins including Italy · Germany · Netherlands.
Latest developments
2026-11-02 — Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results | Nasdaq (nasdaq.com)
2026-04-10 — SCOHIA Grants Neurocrine Biosciences Exclusive Worldwide Rights to SCO‑483, a Novel Selective Melanocortin 2 Receptor Antagonist | SCOHIA PHARMA, Inc. (scohia.com)
2026-04-06 — Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio – Soleno Therapeutics Inc. (soleno.life)
2026-04-06 — Neurocrine expands into metabolic diseases with $2.9 billion Soleno buyout | Reuters (reuters.com)
2026-01-08 — Immedica to acquire Neurocrine Group Limited, Neurocrine Biosciences' European rare commercial business | Immedica (immedica.com)
2025-12-16 — Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology (prnewswire.com)
Facilities
Neurocrine Biosciences is headquartered in San Diego, California. Public sources also reference these locations:
San Diego, CA — prnewswire.com
Company details
Neurocrine maintains a supply chain spanning Europe, with documented shipments from suppliers in Italy, Germany, Switzerland, and the Netherlands. Neurocrine Biosciences was founded in 1992, has an estimated 1,000-5,000 employees, and is headquartered in San Diego, California. On the LightSource stability read it is rated "Established & active": 34 years in operation (founded 1992). 3 US import shipments on record.
Frequently asked questions
What does Neurocrine Biosciences do?
Neurocrine Biosciences is a biopharmaceutical company founded in 1992 and headquartered in San Diego, California, with 1,000–5,000 employees and estimated revenue of $1–5 billion. It develops FDA-approved treatments and investigational therapies for neurological, neuroendocrine, and neuropsychiatric disorders, serving patients with movement disorders and rare pediatric epilepsies. The company acquired Soleno Therapeutics in 2026 to expand into metabolic and endocrine rare diseases.
Where is Neurocrine Biosciences headquartered?
Neurocrine Biosciences is headquartered in San Diego, California (6027 Edgewood Bend Ct, San Diego, California, 92130-8235).
When was Neurocrine Biosciences founded?
Neurocrine Biosciences was founded in 1992.
How big is Neurocrine Biosciences?
Neurocrine Biosciences has an estimated 1,000-5,000 employees, with revenue in the $1-5B range (estimated).
Does Neurocrine Biosciences import from overseas suppliers?
US customs bill-of-lading records show 3 inbound shipments for Neurocrine Biosciences, with top origins including Italy · Germany · Netherlands.
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
